Publikationen - Dr. Katja Tomczak

Wichtige Veröffentlichungen:

Sobczak K, Willing A, Kusche K, Bangel N and Weber WM. Amiloride-sensitive sodium absorption is different in vertebrates and invertebrates. Am J Physiol Regul Integr Comp Physiol 292: R2318-R2327, 2007.

 

Kusche-Vihrog K, Sobczak K, Bangel N, Wilhelmi M, Nechyporuk-Zloy V, Schwab A, Schillers H and Oberleithner H. Aldosterone and amiloride alter ENaC abundance in vascular endothelium. Pflugers Arch 455: 849-857, 2008.

 

Bangel N, Dahlhoff C, Sobczak K, Weber WM and Kusche-Vihrog K. Upregulated expression of ENaC in human CF nasal epithelium. J Cyst Fibros 7: 197-205, 2008.

 

Sobczak K, Segal A, Bangel-Ruland N, Semmler J, Van DW, Lindemann H, Heermann R and Weber WM. Specific inhibition of epithelial Na+ channels by antisense oligonucleotides for the treatment of Na+ hyperabsorption in cystic fibrosis. J Gene Med 11: 813-823, 2009.

 

Sobczak K, Bangel-Ruland N, Semmler J, Lindemann H, Heermann R and Weber WM. Antisense oligonucleotides for therapy of cystic fibrosis. Inhibition of sodium absorption mediated by ENaC in nasal epithelial cells. HNO 57: 1106-1112, 2009.

 

 

 

 

Sobczak K, Bangel-Ruland N, Leier G and Weber WM. Endogenous transport systems in the Xenopus laevis oocyte plasma membrane. Methods 51: 183-189, 2010.

 

Bangel-Ruland N, Sobczak K, Christmann T, Kentrup D, Langhorst H, Kusche-Vihrog K and Weber WM. Characterization of the epithelial sodium channel delta-subunit in human nasal epithelium. Am J Respir Cell Mol Biol 42: 498-505, 2010.

 

Leier G, Bangel-Ruland N, Sobczak K, Knieper Y and Weber WM. Sildenafil Acts as Potentiator and Corrector of CFTR but Might be not Suitable for the Treatment of CF Lung Disease. Cell Physiol Biochem 29: 775-790, 2012.

 

Clark KL, Hughes SA, Bulsara P, Coates J, Moores K, Parry J, Carr M, Mayer RJ, Wilson P, Gruenloh C, Levin D, Darton J, Weber WM, Sobczak K, Gill DR, Hyde SC, Davies LA, Pringle IA, Sumner-Jones SG, Jadhav V, Jamison S, Strapps WR, Pickering V and Edbrooke MR. Pharmacological Characterization of a Novel ENaCalpha siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis. Mol Ther Nucleic Acids 2: e65, 2013.

 

Bangel-Ruland N, Tomczak K, Fernandez FE, Leier G, Leciejewski B, Rudolph C, Rosenecker J and Weber WM. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy. J Gene Med 15: 414-426, 2013.